ABP 215

Modify Date: 2024-04-02 09:47:29

ABP 215 structure	Common Name	ABP 215
	CAS Number	1438851-35-4	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of ABP 215

ABP 215 (Bevacizumab-awwb), a Bevacizumab (Bevacizumab (HY-P9906)) biosimilar, is a humanized IgG1 monoclonal antibody targeting VEGFA (VEGFR). ABP 215 has anticancer effects, and can be used metastatic colorectal cancer (mCRC) research[1][2].

Name	ABP 215

Description	ABP 215 (Bevacizumab-awwb), a Bevacizumab (Bevacizumab (HY-P9906)) biosimilar, is a humanized IgG1 monoclonal antibody targeting VEGFA (VEGFR). ABP 215 has anticancer effects, and can be used metastatic colorectal cancer (mCRC) research[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Protein Tyrosine Kinase/RTK >> VEGFR
In Vitro	ABP 215 (Bevacizumab-awwb) 与 VEGF-A 结合，阻止 VEGF-A 与内皮细胞表面的 VEGF 受体结合，抑制内皮细胞增殖和新血管形成，从而导致肿瘤脉管系统正常化。
References	[1]. Neungseon Seo, et al. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab. MAbs. 2018 May/Jun;10(4):678-691. [2]. Whitney Rhodes, et al. Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer. Future Oncol. 2021 Dec;17(36):5119-5127.

No Any Chemical & Physical Properties

ABP 215

Use of ABP 215

Names

ABP 215 Biological Activity

Chemical & Physical Properties